Hemispherx BioPharma, Inc (NYSE:HEB) saw a significant decline in short interest in October. As of October 13th, there was short interest totalling 1,044,475 shares, a decline of 5.1% from the September 29th total of 1,100,251 shares. Currently, 3.8% of the shares of the stock are sold short. Based on an average daily volume of 409,699 shares, the days-to-cover ratio is currently 2.5 days.

A hedge fund recently raised its stake in Hemispherx BioPharma stock. Vanguard Group Inc. raised its position in shares of Hemispherx BioPharma, Inc (NYSE:HEB) by 0.6% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 453,805 shares of the specialty pharmaceutical company’s stock after buying an additional 2,709 shares during the quarter. Vanguard Group Inc. owned about 1.56% of Hemispherx BioPharma worth $227,000 as of its most recent SEC filing.

Hemispherx BioPharma (NYSE HEB) opened at 0.3299 on Wednesday. Hemispherx BioPharma has a one year low of $0.30 and a one year high of $1.15. The stock’s market cap is $9.62 million. The stock’s 50 day moving average price is $0.33 and its 200 day moving average price is $0.46.

Hemispherx BioPharma (NYSE:HEB) last released its earnings results on Monday, August 14th. The specialty pharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter. Hemispherx BioPharma had a negative return on equity of 75.57% and a negative net margin of 1,029.58%. The business had revenue of $0.21 million for the quarter. Equities analysts predict that Hemispherx BioPharma will post $0.00 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Hemispherx BioPharma, Inc (HEB) Sees Large Drop in Short Interest” was posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/10/25/hemispherx-biopharma-inc-heb-sees-large-drop-in-short-interest.html.

About Hemispherx BioPharma

Hemispherx Biopharma, Inc (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company’s segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon.

Receive News & Ratings for Hemispherx BioPharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.